CIK 0001513525 · Non-accelerated filer<br>Smaller reporting company
Azora Therapeutics, Inc. (DE)
Sign in to watch- Ticker
- AZR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 800667150
- Phone
- 434-422-9800
- Business address
- 16501 VENTURA BLVD, SUITE 400, ENCINO, CA, 91436
- Former names
- ADIAL PHARMACEUTICALS, INC., Adial Pharmaceuticals, L.L.C., ADial Pharmaceuticals, L.L.C.
- 4 Open-market sale Chief Medical Officer sold 150,000 shares at $1.00 ($150,000)
- 10-Q Report Quarterly Report
- 8-K Event Executive or director change
- 4 Grant or award Chief Medical Officer acquired 3,187 shares (grant or award)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 8-K Event Shareholder vote results
- 10-Q Report Quarterly Report
- DEF 14A Proxy Proxy Statement
- 8-K Event Material agreement
- 8-K Event Director nominations · Other events
- 10-Q Report Quarterly Report
- 8-K Event Regulation FD disclosure
- 424B3 Offering Prospectus
- EFFECT Other Notice of Effectiveness
- 4 Open-market buy Chief Medical Officer bought 73,100 shares at an average $3.29 ($240,609)
- SC 13D/A Stake Beneficial Ownership Report
- SC 13D/A Stake Beneficial Ownership Report
- S-1/A Offering Registration Statement
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
Page 24 of 30 · 581 filings